ClinicalTrials.gg
RecruitingNCT02114242BIOPARKUpdated Mar 31, 2022

Biomarkers in Parkinsonian Syndromes

An observational study in Parkinsonian Syndromes, Parkinson's Disease and Multiple System Atrophy, sponsored by University Hospital, Bordeaux. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-31.

Primary conditionParkinson DiseaseRegistry: Parkinsonian DisordersReclassifiedWhy we changed it
Registry
Parkinsonian Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Parkinson Disease
Why
  1. The study's listed conditions name Parkinson Disease, a narrower term within Parkinsonian Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospital, Bordeaux · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2013; still recruiting 12 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Parkinson Disease by University Hospital, Bordeaux — 4 open to participants now, 4 under way, none of them phase 3. Parkinson Disease · University Hospital, Bordeaux.

Started
2013
with 1 other
Observational
2 of 14
1 open now
Registered
4th of 14
by date

Among the 14 studies in Parkinson Disease by University Hospital, Bordeaux, this one is one of 2 that started in 2013, is one of 2 observational ones, and was the 4th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

4 of the 14 studies in Parkinson Disease by University Hospital, Bordeaux are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Parkinson Disease by University Hospital, Bordeaux, or all of them as a file.
02

Study summary

Parkinson disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are neurodegenerative disorders. PD and MSA are alpha-synucleinopathies, which are characterized by the abnormal accumulation of alpha-synuclein, while tau protein accumulates in PSP. The development of biological markers for the diagnosis and prognosis in PD, MSA and PSP remains an unmet need. Such biological markers are crucial for future disease-modification and neuroprotection trials. Alpha-synuclein has a high potential for biomarker development since it constitutes the pathological hallmark feature in PD and MSA. The oligomeric alpha-synuclein seems to be particularly involved in abnormal protein aggregation in alpha-synucleinopathies.

The main objective is to compare oligomeric alpha-synuclein CSF levels between PD, MSA and PSP patients. PD and MSA patients will receive Cerebrospinal Fluid (CSF) and blood sampling at two study visits (baseline and after 12 months). Major secondary objectives are (i) to assess potential associations between the biomarker and clinical measures of disease severity and progression in MSA and PSP, and (ii) to assess the variation of the biomarker and its correlation to disease severity and progression in PD, MSA and PSP.

Read the detailed description

The differential diagnosis between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy can be very difficult in early disease. PD, MSA and PSP are neurodegenerative disorders. PD and MSA belong to the alpha-synucleinopathies, which are characterized by the abnormal accumulation of alpha-synuclein. Alpha-synuclein accumulates in intraneuronal Lewy bodies in PD patients and as intracytoplasmic glial inclusions in MSA. In PSP, tau protein accumulates in neurons and glia cells while alpha-synuclein deposits are only found to a small extend.

The development of biological markers for the diagnosis and prognosis of PD, MSA and PSP remains an unmet need. Beyond guiding clinical decision-making, such biological markers are crucial for future disease-modification and neuroprotection trials.

Alpha-synuclein has a high potential for biomarker development since it constitutes the pathological hallmark feature of PD and MSA. The oligomeric alpha-synuclein fraction whose CSF levels are increased in PD seems to be particularly involved in abnormal protein aggregation in alpha-synucleinopathies.

The main objective of the study is to compare oligomeric alpha-synuclein CSF levels between PD, MSA and PSP patients. Secondary objectives are (i) to compare total alpha-synuclein levels and the index total/oligomeric alpha-synuclein between PD, MSA and PSP, (ii) to study the correlation and concordance between CSF and plasma levels of total and oligomeric alpha-synuclein, (iii) to assess potential associations between the biomarker and clinical measures of disease severity and progression and (iv) to assess the variation of the biomarker over time and its correlation to disease severity and progression.

03

Conditions studied

  • Parkinsonian Syndromes
  • Parkinson's Disease
  • Multiple System Atrophy
  • Progressive Supranuclear Palsy

Keywords

  • Parkinson's disease
  • multiple system atrophy
  • progressive supranuclear palsy
  • alpha-synuclein
04

In context

Parkinson Disease Reclassified

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

This study's planned enrollment of 100 is close to the median of 96 across 1,088 observational studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.

Compared within Parkinson Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Parkinsonian Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients suffering from parkinson disease or multiple system atrophy or progressive supranuclear palsy.

Eligibility criteria

Patients receiving anticoagulants, showing abnormal coagulation on blood testing or thrombocytopenia are excluded from this study.

Patients showing more than 500 erythrocytes per mm3 of LCR are excluded from this study.

  • PD patients

    • inclusion criteria:

      • Patients suffering from PD according to clinical criteria (Hughes et al, 1992)
      • Written
      • Patient covered by the national health system
    • exclusion criteria:

      • Patient under tutelage
      • patient covered by the national health system
  • MSA patients

    • inclusion criteria:

      • Patients suffering from "possible" or "probable" MSA according to clinical consensus criteria (Gilman et al, 2008), age > 30
      • Written informed consent
      • Patient covered by the national health system
    • exclusion criteria:

      • UMSARS IV score >4 points
      • Patient under tutelage
  • PSP patients

    • inclusion criteria:

      • Patients suffering from PSP according to NNIPPS trial criteria (Bensimon et al., 2009), age > 40
      • Written informed consent
      • Patient covered by the national health system
    • exclusion criteria:

      • PSPRS item 26 score >3 points
      • Patient under tutelage
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Parkinson's disease patients

    Patients suffering from Parkinson desease

    Other: clinical measures of disease severity and progression

  • multiple system atrophy patients

    Patients suffering from "probable" multiple system atrophy according to clinical consensus criteria and age \> 30

    Other: CSF, blood and urine sampling · Other: clinical measures of disease severity and progression

  • progressive supranuclear palsy

    Patients suffering from progressive supranuclear palsy and age \> 40

    Other: CSF, blood and urine sampling · Other: clinical measures of disease severity and progression

Interventions

  • OtherCSF, blood and urine sampling

    PSP and MSA patients will receive CSF and blood sampling at two study visits (baseline and after 12 months).

  • Otherclinical measures of disease severity and progression

    Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)

07

What researchers measure

Primary outcomes

  1. Concentration of oligomeric alpha-synuclein in cerebrospinal fluid

    Time frame: at day 0 (inclusion) and one year after inclusion

Secondary outcomes

  1. Total alpha-synuclein concentration in CSF, oligomeric/total alpha-synuclein ratio in CSF

    Time frame: At inclusion (Day 0) and one year after inclusion

  2. Oligomeric and total alpha-synuclein concentration in plasma, oligomeric/total alpha-synuclein ratio in plasma

    Time frame: At inclusion (Day 0) and one year after inclusion

  3. Alpha-synuclein levels in relation to disease severity and progression, disease duration and age

    Time frame: At inclusion (Day 0) and one year after inclusion

  4. Variation of alpha-synuclein levels between first and second sampling

    Time frame: At inclusion (Day 0) and one year after inclusion

08

Study locations

2 of 3 sites recruiting
  • CHU de Limoges
    Limoges, 87000, France
    Recruiting
    • Frédéric Torny, MD · Contact
    • Frédéric Torny, MD · Principal investigator
    • Philippe Couratier, Pr · Sub investigator
  • CHU de Bordeaux
    Pessac, 33640, France
    Recruiting
    • Wassilios MEISSNER, Pr · Contact
    • Wassilios MEISSNER, Pr · Principal investigator
    • François TISON, Pr · Sub investigator
    • Alexandra Foubert-Samier, MD · Sub investigator
    • Olivier Flabeau, Md · Sub investigator
  • CHU de Toulouse
    Toulouse, 31000, France
    Not yet recruiting
    • Olivier RASCOL, Pr · Contact
    • Olivier RASCOL, PR · Principal investigator
    • Anne Pavy-Le Traon, MD · Sub investigator
    • Christine Brefel-Courbon, Dr · Sub investigator
    • Fabienne Ory-Magne, Dr · Sub investigator
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2013 (actual). Primary completion is estimated for Dec 2023, 120 months after the start.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 120 months is above that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2014
First posted
Apr 15, 2014
StartActual
Dec 16, 2013
Primary completionEst.
Dec 16, 2023
CompletionEst.
Dec 16, 2025
Last update
Mar 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02114242
Responsible party
Sponsor
First posted
Apr 15, 2014
Start date
Dec 16, 2013
Primary completion
Dec 16, 2023 (estimated)
Completion
Dec 16, 2025 (estimated)
Last update
Mar 31, 2022

Study contacts

Wassilios MEISSNER, Pr
Contact
wassilios.meissner@chu-bordeaux.fr
Wassilios MEISSNER, Pr
principal investigator · University Hospital, Bordeaux
Rodolphe THIEBAUT, MD
study chair · University Hospital, Bordeaux

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion